BMO Capital Markets reissued their outperform rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a research report sent to investors on Wednesday, September 6th. The firm currently has a $99.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $105.00.
Several other equities research analysts have also recently weighed in on the stock. Vetr cut shares of Alnylam Pharmaceuticals from a strong-buy rating to a buy rating and set a $71.50 price objective for the company. in a research report on Monday, May 15th. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a hold rating to a buy rating and set a $88.00 price target for the company in a report on Wednesday, July 12th. Cowen and Company restated an outperform rating and issued a $100.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, May 17th. Credit Suisse Group restated a hold rating and issued a $50.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Finally, Chardan Capital reduced their price target on shares of Alnylam Pharmaceuticals from $110.00 to $95.00 and set a buy rating for the company in a report on Monday, May 15th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $82.25.
Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 1.77% during mid-day trading on Wednesday, hitting $76.77. The stock had a trading volume of 348,121 shares. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $89.45. The company has a 50-day moving average price of $81.65 and a 200 day moving average price of $68.34. The company’s market cap is $7.04 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same quarter last year, the company earned ($1.05) earnings per share. The company’s quarterly revenue was up 82.9% compared to the same quarter last year. Equities research analysts forecast that Alnylam Pharmaceuticals will post ($5.18) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “BMO Capital Markets Reaffirms “Outperform” Rating for Alnylam Pharmaceuticals, Inc. (ALNY)” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2017/09/15/bmo-capital-markets-reiterates-outperform-rating-for-alnylam-pharmaceuticals-inc-alny.html.
A number of large investors have recently bought and sold shares of ALNY. BlackRock Inc. raised its holdings in Alnylam Pharmaceuticals by 34,755.2% during the 1st quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares during the last quarter. Perceptive Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 831.4% in the 1st quarter. Perceptive Advisors LLC now owns 1,103,475 shares of the biopharmaceutical company’s stock worth $56,553,000 after purchasing an additional 985,000 shares in the last quarter. FMR LLC raised its holdings in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter. FMR LLC now owns 13,723,153 shares of the biopharmaceutical company’s stock worth $1,094,559,000 after purchasing an additional 815,270 shares in the last quarter. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 13.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,419,508 shares of the biopharmaceutical company’s stock worth $512,020,000 after purchasing an additional 759,295 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $53,226,000. Institutional investors own 94.27% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.